366 related articles for article (PubMed ID: 38008185)
21. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
Taha MS; Padmakumar S; Singh A; Amiji MM
Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
[TBL] [Abstract][Full Text] [Related]
22. The Nano-War Against Complement Proteins.
Wang Z; Brenner JS
AAPS J; 2021 Sep; 23(5):105. PubMed ID: 34505951
[TBL] [Abstract][Full Text] [Related]
23. Nanotechnology as a tool to overcome macromolecules delivery issues.
Tundisi LL; Ataide JA; Costa JSR; Coêlho DF; Liszbinski RB; Lopes AM; Oliveira-Nascimento L; de Jesus MB; Jozala AF; Ehrhardt C; Mazzola PG
Colloids Surf B Biointerfaces; 2023 Feb; 222():113043. PubMed ID: 36455361
[TBL] [Abstract][Full Text] [Related]
24. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems.
Liu H; Zhu X; Wei Y; Song C; Wang Y
Biomed Pharmacother; 2023 Jan; 157():114065. PubMed ID: 36481408
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
Du JZ; Li HJ; Wang J
Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
[TBL] [Abstract][Full Text] [Related]
27. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
Bhattacharjee S; Brayden DJ
Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
[TBL] [Abstract][Full Text] [Related]
28. Cell-mediated nanoparticle delivery systems: towards precision nanomedicine.
Cheng R; Wang S
Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38615157
[TBL] [Abstract][Full Text] [Related]
29. Red Blood Cell Inspired Strategies for Drug Delivery: Emerging Concepts and New Advances.
Zhang E; Phan P; Algarni HA; Zhao Z
Pharm Res; 2022 Nov; 39(11):2673-2698. PubMed ID: 35794397
[TBL] [Abstract][Full Text] [Related]
30. Insights into cellular uptake of nanoparticles.
Kafshgari MH; Harding FJ; Voelcker NH
Curr Drug Deliv; 2015; 12(1):63-77. PubMed ID: 25146441
[TBL] [Abstract][Full Text] [Related]
31. Dual and multi-targeted nanoparticles for site-specific brain drug delivery.
Luo Y; Yang H; Zhou YF; Hu B
J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery.
Wang M; Xin Y; Cao H; Li W; Hua Y; Webster TJ; Zhang C; Tang W; Liu Z
Biomater Sci; 2021 Feb; 9(4):1088-1103. PubMed ID: 33332490
[TBL] [Abstract][Full Text] [Related]
33. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P; Subramony JA
J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
[TBL] [Abstract][Full Text] [Related]
34. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
35. Mesoporous silica nanoparticles for pulmonary drug delivery.
García-Fernández A; Sancenón F; Martínez-Máñez R
Adv Drug Deliv Rev; 2021 Oct; 177():113953. PubMed ID: 34474094
[TBL] [Abstract][Full Text] [Related]
36. Nanomedicine approaches in vascular disease: a review.
Gupta AS
Nanomedicine; 2011 Dec; 7(6):763-79. PubMed ID: 21601009
[TBL] [Abstract][Full Text] [Related]
37. Vascular Nanomedicine: Current Status, Opportunities, and Challenges.
Sun M; Sen Gupta A
Semin Thromb Hemost; 2020 Jul; 46(5):524-544. PubMed ID: 31200393
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions.
Moradi Kashkooli F; Jakhmola A; Hornsby TK; Tavakkoli JJ; Kolios MC
J Control Release; 2023 Mar; 355():552-578. PubMed ID: 36773959
[TBL] [Abstract][Full Text] [Related]
39. Oral nanomedicine approaches for the treatment of psychiatric illnesses.
Dening TJ; Rao S; Thomas N; Prestidge CA
J Control Release; 2016 Feb; 223():137-156. PubMed ID: 26739547
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation.
Mills JA; Liu F; Jarrett TR; Fletcher NL; Thurecht KJ
Biomater Sci; 2022 Jun; 10(12):3029-3053. PubMed ID: 35419582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
